Zhu Victoria, Tran Deanna, Banjo Olamide, Onuegbu Rosemary, Seung Hyunuk, Layson-Wolf Cherokee
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):781-788.e2. doi: 10.1016/j.japh.2020.03.013. Epub 2020 Apr 16.
The primary objective of this study was to determine patients' perceptions of pharmacists prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention.
An anonymous, 26-item, cross-sectional survey was administered to individuals and data collection occurred during a 12-week period from January to March 2019.
Individuals were recruited to complete the survey in person at 5 locations of a large grocery-chain pharmacy in Washington, D.C. and Maryland. Inclusion criteria included individuals who were at least 18 years old and able to read and write English. Exclusion criteria included persons living with HIV or acquired immunodeficiency syndrome.
In order to measure perception, participants were asked on the survey to select their level of agreement using a Likert scale from 1 to 5 (1 = strongly disagree, 5 = strongly agree). Researchers analyzed overall perception in addition to differences in perception based on various demographic characteristics.
In total, 117 surveys were collected and analyzed. Most participants were comfortable with pharmacists prescribing PrEP. Notable statistically significant findings included participants who interacted with pharmacists through medication therapy review (4.4, 3.1 [P < 0.05]) and vaccinations (4.3, 3.1 [P < 0.05]) were more likely to agree with pharmacists prescribing PrEP than participants who had no previous interactions with pharmacists. Participants who had previously used PrEP were more likely to agree with pharmacists prescribing PrEP than those who had not used PrEP before.
This study provided a glimpse into patients' perceptions of pharmacists prescribing PrEP. Patients were generally favorable of pharmacists prescribing PrEP; however, there are still barriers to overcome before prescribing PrEP for HIV prevention can feasibly occur in the community setting.
本研究的主要目的是确定患者对药剂师开具暴露前预防（PrEP）药物以预防人类免疫缺陷病毒（HIV）的看法。
对个体进行了一项26项的匿名横断面调查，数据收集于2019年1月至3月的12周内进行。
招募个体在华盛顿特区和马里兰州一家大型连锁杂货店药房的5个地点亲自完成调查。纳入标准包括年龄至少18岁且能够读写英语的个体。排除标准包括感染HIV或获得性免疫缺陷综合征的人。
为了衡量看法，在调查中要求参与者使用1至5的李克特量表（1 = 强烈不同意，5 = 强烈同意）选择他们的同意程度。研究人员除了分析总体看法外，还分析了基于各种人口统计学特征的看法差异。
总共收集并分析了117份调查问卷。大多数参与者对药剂师开具PrEP药物感到放心。值得注意的具有统计学意义的发现包括，通过药物治疗评估（4.4，3.1 [P < 0.05]）和疫苗接种（4.3，3.1 [P < 0.05]）与药剂师互动的参与者比以前没有与药剂师互动的参与者更有可能同意药剂师开具PrEP药物。以前使用过PrEP的参与者比以前未使用过PrEP的参与者更有可能同意药剂师开具PrEP药物。
本研究让我们得以一窥患者对药剂师开具PrEP药物的看法。患者总体上对药剂师开具PrEP药物持赞同态度；然而，在社区环境中切实可行地为预防HIV开具PrEP药物之前，仍有障碍需要克服。
